GoodRx Holdings, Inc. (GDRX) reported $196.03 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 0.4%. EPS of $0.08 for the same period compares to $0.08 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $193.43 million, representing a surprise of +1.34%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Monthly Active Consumers: 5 compared to the 5 average estimate based on three analysts.
- Subscription plans: 671 versus 662 estimated by two analysts on average.
- Revenue- Prescription transactions: $127.29 million versus the four-analyst average estimate of $131.26 million. The reported number represents a year-over-year change of -9.3%.
- Revenue- Other: $4.64 million versus $4.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -14% change.
- Revenue- Pharma manufacturer solutions: $43.37 million compared to the $37.06 million average estimate based on four analysts. The reported number represents a change of +54.4% year over year.
- Revenue- Subscription: $20.72 million versus $20.26 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.7% change.
View all Key Company Metrics for GoodRx here>>>
Shares of GoodRx have returned -27.7% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Free Report: Profiting from the 2nd Wave of AI Explosion
The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.
Investors who bought shares like Nvidia at the right time have had a shot at huge gains.
But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.
Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.
Access AI Boom 2.0 now, absolutely free >>GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
